Ginkgo Biloba Extract

ApprovedSmall molecule

NNational Center for Complementary and Integrative Health (NCCIH)

Ginkgo Biloba Extract is one of 233 small molecule programs targeting Insulin resistance. It is currently in Approved.

Indications

Total Trials

Active Trials

232

Competitors

Pipeline

Status by Indication[3][1]

Indication

Insulin ResistanceActive, not recruiting

Coronary Artery DiseaseActive, not recruiting

TinnitusActive, not recruiting

OtotoxicityActive, not recruiting

MemoryActive, not recruiting

SchizophreniaActive, not recruiting

Mild Cognitive ImpairmentNot yet recruiting

Ischemic StrokeActive, not recruiting

Insulin ResistancePhase 1/Phase 2

Active, not recruiting

Coronary Artery DiseaseApproved

Active, not recruiting

TinnitusPreclinical

Active, not recruiting

OtotoxicityPhase 2

Active, not recruiting

MemoryApproved

Active, not recruiting

SchizophreniaPreclinical

Active, not recruiting

Mild Cognitive ImpairmentApproved

Not yet recruiting

Ischemic StrokePreclinical

Active, not recruiting

Competition

Competitive Landscape

583 competitors in Schizophrenia

#DrugCompanyPhaseTrials

Ginkgo Biloba Extract

NNational Center for Complementary and Integrative Health (NCCIH)

Approved

2 2

Celexa

AbbVie

Preclinical

4 3

Resotran

Takeda

Preclinical

1 4

Depakote

Lunesta

3 6

Comtan

Orion Corporation, Orion Pharma

Preclinical

1 7

Permax

VValeant Pharmaceuticals

Preclinical

1 8

Catapres

Boehringer Ingelheim

Preclinical

1 9

Persantine

Boehringer Ingelheim

Preclinical

1 10

Inversine

TTargacept Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

N/ANot yet recruiting

Ischemic Stroke

NCT06140888

Q4 2028

ApprovedNot yet recruiting

Mild Cognitive Impairment

NCT07579689

Clinical

Trials by Indication[1]

Cognitive Decline2 trials

Preventing Cognitive Decline With Alternative Therapies

Completed·NNational Center for Complementary and Integrative Health (NCCIH)·Phase 3·NCT00010920

Modulation of Attention in Event Related Potential (ERPs) as a Marker of Early Cognitive Decline by Ginkgo Biloba

Unknown status·JJean-François Démonet·N/A·NCT04121728·16 enrolled

Tinnitus2 trials

Repetitive Transcranial Magnetic Stimulation for Chronic Subjective Tinnitus

Completed·UUniversity Hospital Ostrava·N/A·NCT03425045·40 enrolled

Short-term Oral Prednisone for Acute Subjective Tinnitus

Completed·EEye & ENT Hospital of Fudan University·N/A·NCT05591144·146 enrolled

Schizophrenia2 trials

Ginkgo Biloba Extract in the Treatment of Schizophrenia

Completed·—·N/A·NCT05258123·100 enrolled

Ginkgo Biloba Extract for Schizophrenia

Completed·—·N/A·NCT01524380·124 enrolled

Insulin resistance1 trial

Ginkgo Biloba Extract and the Insulin Resistance Syndrome

Completed·NNational Center for Complementary and Integrative Health (NCCIH)·Phase 1/2·NCT00032474·150 enrolled

Ischemic stroke1 trial

Effect of Ginkgo Biloba Extract on Cognitive Function in Acute Ischemic Stroke

Not yet recruiting·YYi Yang·N/A·NCT06140888·356 enrolled

5 more indications

Ototoxicity1 trial

The Protective Effect of Ginkgo Biloba Extract on Cisplatin-induced Ototoxicity in Humans

Completed·UUniversity of Brasilia·Phase 2·NCT01139281·15 enrolled

Coronary Artery Disease1 trial

Study Effects of Ginkgo Biloba Extract on Endothelial Cell Function and Genetic Effects on the Response to Ginkgo Biloba Extract in Diabetic Patients With Stable Coronary Artery Disease

Unknown status·TTaipei Veterans General Hospital, Taiwan·Phase 4·NCT01038050·60 enrolled

Memory1 trial

Treatment for Early Memory Loss

Completed·UUniversity of Iowa·Phase 4·NCT00042172·40 enrolled

Mild Cognitive Impairment1 trial

Effect of Gingko Biloba on the Blood Biomarkers in Mild Cognitive Impairment Patients With Alzheimer's Disease

Not yet recruiting·HHanyang University·Approved·NCT07579689·120 enrolled

Unspecified2 trials

Role of Ginkgo Biloba Extract in IUGR

Completed·—·Phase 2·NCT02425436·226 enrolled

Different Dosing Regimens of STOP-AST

Unknown status·EEye & ENT Hospital of Fudan University·N/A·NCT06124703·162 enrolled

Sources

References

[1]
ClinicalTrials.gov — 14 trial records for Ginkgo Biloba Extract. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Ginkgo Biloba Extract compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Ginkgo Biloba Extract. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National Center for Complementary and Integrative Health (NCCIH) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: NNational Center for Complementary and Integrative Health (NCCIH)

Ginkgo Biloba Extract

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q4 2028

Trials by Indication[1]

Cognitive Decline2 trials

Tinnitus2 trials

Schizophrenia2 trials

Insulin resistance1 trial

Ischemic stroke1 trial

Ototoxicity1 trial

Coronary Artery Disease1 trial

Memory1 trial

Mild Cognitive Impairment1 trial

Unspecified2 trials

References

Drug Info

Quick Facts

Related News